Chen Zhao

So proud of the many decades of the NCI’s funding discovery science and translational research that is led to such marked improvements for patients with cancer. #YourNCI youtu.be/pZf0KLswtd0

Today’s KRAS win didn’t start today. It took decades. Daraxonrasib nearly doubled survival in pancreatic cancer. That’s extraordinary! But lets zoom out for a sec: ▪️KRAS was called “undruggable.” ▫️NIH quietly poured ~$172M behind it. ▫️Funding grew 9x. 💡One insight (Shokat lab, 2013) changed everything. This is how breakthroughs are supposed to work: public money → basic insight academic labs → first leap industry → drug + survival curve Today’s headline has MANY authors. Congrats to @Revolution_Med and every scientist who stayed on KRAS when it looked impossible. 🎈this is what compounding science truly looks like = = = = = Source: NIH RePORTER via @Jori_health = = = = =

📄 Our review in @JTOonline is now out: Antibody–Drug Conjugates in Small-Cell Lung Cancer: DLL3, B7-H3, TROP2 and Beyond DOI: 10.1016/j.jtho.2026.103726 Key question: not just whether ADCs work in relapsed #SCLC, but how to sequence them with DLL3-directed T-cell engagers.

Value of retreatment with alternate selective RET inhibitors in NSCLC discussed @CCR_AACR. When one agent discontinued for toxicity, switching to an alternate had RR 67%, mPFS 9.9m but AEs re-occurred in 64%. When switched due to toxicity, RR 23%, PFS 7m. aacrjournals.org/clincancerres/…

Our double lung transplant results for lung-limited lung cancers at Northwestern are presented at #ELCC26 🫁✨ Both active patients and those with recent (<5yr) cancer history are doing well overall 💪📊 @LurieCancer @OncoAlert @NUFeinbergMed @NorthwesternMed @NM_Lung

Retrospective report on 636 pts with KRAS G12V NSCLC @CCR_AACR. 94% with history of smoking. Co-mutations common: 40% TP53, 30% STK11, 29% KEAP1. Trend toward higher CD8+ T-cell infiltration vs non-G12V subtypes. Favorable outcomes with immunotherapy. aacrjournals.org/clincancerres/…

Should we do molec testing on all NSCLCs? Answer: YES @JTOonline - 82328pts - 35.1% AGA+ (adeno=45.8% adenosq=40.9% sarcomatoid=29.1% NOS=27.6%, LCC=21.1% sq=6.5%) - age, sex, region assoc seen Congrats @Al3ssandroRusso @ChristianRolfo @oncoalert #LCSM jto.org/article/S1556-…

The TIGIT catastrophe‼️ 30 agents 220 trials ~50,000 patients >$3B+ invested 0 approvals. This is herding in drug development. In BMJ Oncol we examine why it happens, the hidden costs, and what needs to change. It’s already happening again in ADCs... 🔗:bmjoncology.bmj.com/content/5/1/e0…